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Abstract
Reactivating latent HIV is key to depleting the virus
reservoir in AIDS patients. A recent paper has described
the rationale for and discovery of a new class of drugs -
transcriptional noise enhancers - that can synergize with
conventional transcription activators to more effectively
reactivate latently infected T cells. As well as describing a
promising new strategy in the bid to find a cure for AIDS,
this study more broadly highlights the utility of exploring
drug combinations in treatment of human disease.
It has been over 30 years since HIV was discovered as
the cause of AIDS, which has taken over 30 million lives,
but we have yet to find a vaccine or a cure for this dis-
ease. Developing a cure for AIDS has been hampered by
the difficulty of eradicating quiescent viruses that are in-
tegrated into the genomes of long-lived CD4
+ memory
T cells but are inactive for gene expression and replica-
tion [1]. These so-called latent viruses can persist over
long periods of time and can be reactivated under cer-
tain circumstances to initiate new rounds of replication
[2]. HIV-infected individuals therefore need life-long
treatment to suppress viral replication.
A leading strategy that is being followed to develop a
cure for AIDS is to reactivate the latent viruses so that
the reservoir of latently infected T cells will be killed by
either the replicating viruses or the immune system (the
‘shock and kill’ strategy) [3]. In combination with anti-
retroviral therapy (ART), the reactivation strategy might
enable the eradication of the virus in patients. However,
currently available small molecules capable of reactivat-
ing HIV have been shown to be insufficient to fully
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activate the latently infected T cells in cell-based assays
and clinical trials [4,5]. More potent small molecules
and their combinations are clearly needed to realize the
potential of the shock and kill strategy.
Dar et al. now report in Science [6] that a surprising
class of small molecules might help the currently avail-
able HIV-reactivating drugs to further enhance reactiva-
tion efficiency. Single-cell gene expression analysis has
demonstrated a non-uniform distribution of gene ex-
pression in otherwise identical cells. The variance of
gene expression from the mean is referred to as noise;
the greater the variation, the greater the noise. The class
of molecules identified by Dar et al. [6] increases the
variation of transcriptional activity (transcriptional noise)
of a reporter under the control of the HIV long terminal
repeat (LTR) promoter. In contrast to conventional tran-
scriptional reactivators, these noise enhancers do not
alter the mean transcriptional activity.
Based on computational simulations, Dar et al. [6] rea-
soned that increasing the noise level of gene expression
might have synergistic effects with conventional tran-
scriptional reactivators to enhance HIV reactivation
from latency. Following on from this hypothesis, the au-
thors [6] screened for enhancers of noise from a library
of 1,600 bioactive small molecules. The screen used a
Jurkat cell line (immortalized human T lymphocytes)
with an integrated copy of a short-lived green fluores-
cent protein gene (d2GFP) driven by the LTR promoter
of HIV, as the short half-life of the fluorescent protein
faithfully reports on transcriptional efficiency [7].
The authors identified 110 compounds that showed
noise enhancing activity but not direct transcription up-
regulation activity. They further tested the activity of
these molecules in a dual reporter system expressing the
short-lived d2GFP and a stable mCherry fluorescent pro-
tein. Based on their computational model, the noise level
of the abundance of a stable protein is only minimally
affected by transcriptional noise. With this in mind, the
authors [6] eliminated those compounds that affect the
noise of both d2GFP and mCherry expression, leaving
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cells with a broad spectrum of integration sites, they
confirmed that these compounds increase transcriptional
noise regardless of integration site. This is important be-
cause the ability to affect the noise at all expression
levels means that potentially latent HIV integrants in
many genomic locations and with different basal levels
of expression may all be responsive to these compounds.
Remarkably, the authors [6] found that the majority of
the 85 compounds demonstrated synergistic reactivation
activities with molecules that have conventionally been
used as transcriptional activators of latent HIV (tumor
necrosis factor (TNF), prostratin or phorbol esters such
as PMA) in three latently infected cell lines and in pri-
mary T cells. Just as the authors’ theory predicted [6],
the degree of synergy for a given compound shows a
strong correlation with the magnitude of noise enhance-
ment, suggesting that the synergy indeed stems from the
noise enhancing activity. In the other direction, a noise
suppressor was also tested in combination with TNF and
shown to antagonize the reactivation activity of TNF.
Notably, the cytotoxicity of the combinations of noise
enhancers and transcriptional activators is significantly
lower than that of a leading combination of transcrip-
tional activators (SAHA plus prostratin) with a similar
degree of reactivation efficiency. This suggests an im-
proved therapeutic window of the noise enhancer/tran-
scription activator combinations. HIV reactivation might
be particularly well-suited as a target for this strategy be-
cause the goal is the activation of a forward-feeding
transcriptional loop that involves the viral Tat protein
and the TAR RNA. Increasing the noise increases the
frequency with which a cell might surpass the threshold
needed to flip the Tat-TAR circuit on, which then main-
tains itself.
What is the mechanism of noise enhancement? The
authors report that many known chromosome remode-
lers, such as histone deacetylase inhibitors, DNA methy-
lation inhibitors and bromodomain inhibitors, can
increase transcriptional noise. This property could be ex-
plained by their ability to make the chromosome con-
texts more accessible to the transcriptional machinery.
The top candidates from the screen, however, have di-
verse known functions that include microtubule inhibi-
tors, an anti-inflammatory agent, an estrogen receptor
ligand and a DNA/RNA synthesis inhibitor. It is not ob-
vious how such an array of compounds can each work
specifically to increase the transcriptional noise of HIV.
Plausible explanations include off-target effects of these
compounds or that there are many regulatory pathways
that can modulate HIV transcription. Three cell cycle in-
hibitors, including two microtubule depolymerization in-
hibitors and a DNA/RNA synthesis inhibitor, are among
the top 10 hits, which seems to suggest that cell cycle
inhibition might have a role in the noise enhancement.
Further studies are needed to elucidate the mechanisms
of action of these noise enhancing compounds, which
will shed light on how transcription noise is controlled
in general.
In this study, Dar et al. [6] developed a novel approach
to screen for synergistic HIV reactivating drug combina-
tions. This approach - noise enhancement - may have
broader implications for drug discovery targeting other
diseases. This work also highlights the power and neces-
sity of systematically searching for drug combinations
rather than combining drugs with the desired activity in-
dividually. This is clearly demonstrated by the fact that
most of the noise enhancers have no effect on reactiva-
tion individually so they would have been missed by
conventional single drug screenings. Complete HIV re-
activation is a tall order unlikely to be achieved by a sin-
gle agent. Neither the current leading cocktails nor the
noise enhancer plus transcriptional activator combina-
tions developed in this study can fully reactivate the la-
tently infected cells in vitro. It might be even more
difficult to reactivate latent virus in vivo given that cer-
tain tissues harboring latent virus, such as the central
nervous system and gut-associated lymphoid tissue, are
difficult to penetrate with drugs [4]. Drug combinations
with new activities and innovative drug delivery methods
will likely be needed to accomplish this task.
Importantly, mere screening for reactivation might be
insufficient as the ultimate goal is to kill the reactivated
cells. An ideal drug cocktail would be able to reactivate
and promote the death of the reactivated cells. Recent
new methods of high throughput screening [8] and im-
munotherapy [9,10] might be helpful to achieve this lofty
goal. This eye-opening approach developed by Dar et al.
[6] reminds us to keep an open mind to all possibilities
in the search to end the AIDS pandemic.
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